1. Introduction {#s0005}
===============

Gastric cancer (GC) is an aggressive neoplasm that is associated with an extremely poor prognosis ([@bb0025]). Although the incidence of GC has been recently declining in several countries, it is still the second most common cause of cancer related mortality worldwide ([@bb0170]). *Helicobacter pylori* (*H. pylori*), host genetic make-up and dietary factors are the major contributors in the pathogenesis of GC ([@bb0090]). The annual incidence of GC is high (32--115 per 100,000 population) in some areas of the world such as Japan and China despite low sero-prevalence of *H. pylori* (40--50%) ([@bb0180]). In contrast, in some areas of the world such as India, a lower proportion of subjects develop GC in spite of high prevalence of *H. pylori* infection ([@bb0180; @bb0080]). This incongruent observation might suggest that environmental factors (other than *H. pylori* infection) and host genetic factors may influence the clinical outcome of *H. pylori* infection ([@bb0015; @bb0165]).

GC develops through multiple steps and etiological factors are diverse. Pre-cancerous lesions of the stomach such as chronic atrophic gastritis, intestinal metaplasia (IM) and dysplasia precede the development of the GC ([@bb0040; @bb0190]). Chronic inflammation with sustained proliferation has been generally accepted as a risk factor for cancer, including GC ([@bb0045; @bb0020]). It is well known that persistent *H. pylori* infection causes inflammation (chronic gastritis), which is thought to progress to pre-cancerous lesions such as IM and finally to invasive GC. Chronic inflammation develops in genetically susceptible hosts with defective mucosal defense mechanisms or de-regulated immune responses by cytokines ([@bb0045]). Genetic variations in cytokine genes can influence the inter-individual responses and disease susceptibility. The role of genes that encode pro- and anti-inflammatory cytokines and their circulating levels are well established in other gastro-duodenal diseases ([@bb0195]). Although the link between inflammation and GC has been well established, the mechanisms involved in the process remains unclear.

Pro- and anti-inflammatory cytokines modulate the inflammatory response of the gastric mucosa. Pro-inflammatory chemotactic cytokine (IL-8) activates the inflammatory cells by the migration of neutrophils, mononuclear phagocytes, and mast cells and plays a major role in acquired immune responses ([@bb0045; @bb0145]). On the other hand, anti-inflammatory cytokine (IL-10, a product of Th2 cells) is a potent factor for suppressing inflammatory and neoplastic processes by inhibiting IFN-γ production and antigen-specific T-cell activation ([@bb0030; @bb0095]). Balance between pro- (IL-8) and anti-inflammatory (IL-10) cytokines may influence the degree of inflammation, which is a potential factor in the development of gastritis and GC ([@bb0100; @bb0240]).

Cytokine polymorphisms are the most studied genetic factor and are associated with the risk of GC in many regions, but have not been studied extensively in an Indian population ([@bb0055; @bb0215]). Therefore, we investigated the association between pro- (IL)-8-251 T/A (rs4073) and anti-inflammatory (IL-10)-1082 G/A (rs1800896) and -819/592 C/T (rs1800871) gene polymorphisms with their circulating levels among patients with GC as compared to controls (functional dyspepsia \[FD\] and healthy controls \[HC\]), with particular attention towards the relationship between *H. pylori* infection and the presence of precancerous lesions such as IM and gastritis.

2. Methods {#s0010}
==========

2.1. Sample size calculation and study subjects {#s0015}
-----------------------------------------------

Quanto program version 1.1.1 (<http://hydra.usc.edu/gxe>) was used for sample size estimation for each genetic marker. The sample size for the study on IL-8-251 T/A gene polymorphism was calculated with input of the following parameters: case--control study design (1:1), significance level (α) \< 0.05 (2 sided), model of inheritance was log additive (which is the most suitable model for the polygenic diseases), genetic effect (odds ratio) ≤ 1.5 or ≥ 2.0, power 80%, proportion of population expected to have GC 0.0001% and proportion of control expected to have IL-8-251A variant allele: 39% as reported from India ([@bb0010]). The sample size was estimated to be 198 subjects in each group.

Similarly, the sample size for the study on IL-10 gene polymorphisms was calculated keeping all the above mentioned parameters the same and IL-10-1082 "G" allele frequency as 37% and IL-10-819 "T" variant allele frequency as 35% among control population as reported from our institute. The sample size was estimated to be 200 and 204 subjects in each group, respectively ([@bb0115; @bb0005]).

Two hundred patients with histologically confirmed non-cardia GC were included in the study. One hundred eighty-two age- and gender-matched patients with FD were included as a disease control ([@bb0150]). Subjects who had received anti-microbial therapy, H~2~-receptor blockers, proton-pump inhibitors and non-steroidal anti-inflammatory drugs within 15 days before were excluded. Two hundred and fifty volunteers from the community (age- and sex-matched) willing to participate in the study were included as HC. The study protocol was approved by the Institutional Ethics Committee (IEC code: 2013-69-SRF-70) and written informed consent was obtained from all the subjects.

2.2. Esophagogastroduodenoscopy and sample collection {#s0020}
-----------------------------------------------------

Esophagogastroduodenoscopy (EGD) was performed using a video endoscope (Olympus Optical Co Ltd., Tokyo, Japan). Six biopsies were collected in 10% neutral buffered formalin from tumor margins. Hematoxylin and eosin (H & E)-stained sections of endoscopic biopsy or surgically resected specimens were evaluated for confirmation of malignancy. If GC was diagnosed, it was further sub-classified into intestinal or diffuse type on histology using Lauren\'s classification ([@bb0125]). Two to four biopsies were also collected among the patients with GC and FD (each from the antrum and body) from normal looking areas of the stomach for evaluation of *H. pylori* infection, IM and gastritis (graded according to updated Sydney system) ([@bb0065; @bb0035]). This was assessed by an expert pathologist, who was blinded about the endoscopic findings. If the scores in the two biopsies were different, the higher score was accepted.

For genotyping studies, three milliliter blood in ethylene diamine tetra acetic acid (EDTA) was collected from all the patients and controls. Blood samples were collected from all the patients at morning after overnight fasting on the day of EGD. In the healthy subjects, blood samples were also collected similarly early in the morning in fasting state.

2.3. Diagnosis of *H. pylori* infection {#s0025}
---------------------------------------

Enzyme linked immune-sorbent assay (ELISA) was performed for IgG antibodies (HpIgG ELISA) using a commercially available kit (Biohit Oyj, Finland) ([@bb0085]). A cut-off value of antibody concentration ≥ 30 enzyme immune unit (EIU) was considered positive.

2.4. DNA extraction and quantification {#s0030}
--------------------------------------

Genomic DNA was extracted from blood containing EDTA using commercially available kit (AuPrep, Life technologies, India) as per manufacturer\'s instructions. The quantity and purity of DNA were checked by 1.0% agarose gel electrophoresis and also by the ratio of optical density (OD) at 260 nm and 280 nm. It was stored at − 40 °C until use.

2.5. Genotyping of IL-8 and IL-10 polymorphisms {#s0035}
-----------------------------------------------

Genotyping was performed by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR), as described previously ([@bb0115; @bb0105]). In this method, we have used two reactions per samples. One common primer and each allele specific primer were used for each reaction. In IL-8-251 T/A genotyping, alleles were coded as A/A if amplification was seen in A specific primers; T/T when amplification was seen in T specific primers; A/T when amplification was seen in both A as well as T specific primers and the same method was also used for genotyping of IL-10-1082 G/A and -819 C/T. PCR products were run on 2% agarose gel and stained with 5% ethidium bromide. Quality control and assessment was done at every step of the study. If genotyping could not be assessed initially, it was repeated. A molecular base pair marker was included during electrophoresis. To ensure PCR success, an internal control region was amplified from the β-globin. Ten percent of samples from patients and controls were repeated to evaluate the quality of genotyping, which showed 100% concordance.

2.6. Estimation of serum IL-8 and IL-10 levels {#s0040}
----------------------------------------------

Venous blood was clotted for 1 h in gel clot activator based vacutainers (RS Biosciences, USA), then centrifuged for 1000 *g* × 15 min at room temperature. Serum was removed immediately and stored at − 40 °C. IL-8 and IL-10 levels in the serum were estimated by sandwich ELISA based commercially available kits. The assay sensitivity was 0.8 and 2 pg/ml for IL-8 and IL-10 respectively. We have also used the positive and negative controls in every reaction of ELISA (standard dilute provided by BD biosciences, USA).

2.7. Statistical analysis {#s0045}
-------------------------

Categorical data and Hardy--Weinberg\'s equilibrium was evaluated by Chi-squared (χ^2^) test. p-Values less than 0.05 were considered significant. Binary logistic regression was used to estimate risks as odds ratio (OR) with 95% confidence intervals (CI). Patients were categorized on the basis of disease group, presence and absence of *H. pylori* and Lauren\'s classification of GC. Differences among groups for cytokine levels were evaluated using the non-parametric Kruskal--Wallis H and Mann--Whitney U test. Post hoc analysis and Bonferroni\'s correction (a multiple-comparison correction) were applied to significant association in subgroup analysis. In addition, haplotype analysis was used to estimate the frequency of unknown combinations by online software; <http://bioinfo.iconcologia.net/SNPstats> and frequency of different haplotypes was compared among groups by logistic regression; SPSS ver. 15 (SPSS, Inc., Chicago, IL, USA).

3. Results {#s0050}
==========

3.1. Demographic data {#s0055}
---------------------

All the patients and controls were comparable in gender. Patients with GC were also comparable to HC in age. Body weight (BW) was lower among the patients with GC than FD and HC ([Table 1](#t0005){ref-type="table"}).

3.2. Histology of gastric biopsy in patients with GC and FD {#s0060}
-----------------------------------------------------------

Of the 367 patients (both GC and FD), 80/357 (22.4%) had IM and 246/351 (70.1%) had gastritis. Patients with GC had higher frequency of IM than those with FD (64/178 \[36.0%\] vs. 16/179 \[8.9%\], p \< 0.001) but had similar frequency of gastritis (115/176 \[65.3%\] vs. 131/175 \[74.9%\], p = 0.062). Severity of gastritis was similar among patients with GC and FD ([Table 1](#t0005){ref-type="table"}). By Lauren\'s classification (n = 176), 92 (52%) had intestinal and 75 (43%) had diffuse type of tumor. In nine (5%), the tumor was unclassified.

3.3. *H. pylori* seropositivity {#s0065}
-------------------------------

In all, 105 of 176 (59.7%) patients with GC, 121/182 (66.5%) with FD and 168/250 (67.2%) HC were positive for anti-*H. pylori* IgG serology. Anti-*H. pylori* IgG levels were similar among patients with GC and FD but higher than HC ([Table 1](#t0005){ref-type="table"}). Seropositivity of IgG ELISA for *H. pylori* was comparable among different groups (p = 0.235).

3.4. Association between pro-inflammatory (IL-8)-251 T/A genotypes and risk of GC {#s0070}
---------------------------------------------------------------------------------

Frequency of genotypes, and alleles were in Hardy--Weinberg equilibrium among controls (p = 0.801 for FD \[disease control\] and 0.618 for HC). Homozygous variant (AA) was commoner among patients with GC and conferred up to twofold risk in reference to homozygous wild (TT) genotype \[47/200 (23.5%) vs. 35/250 (14%); p = 0.023, OR 1.86, 95% CI 1.09--3.19\] in comparison to HC. Heterozygous (TA) and dominant (TA + AA) models were comparable among all the three groups ([Table 2](#t0010){ref-type="table"}).

3.5. Association between anti-inflammatory (IL-10-1082 G/A and -819/592 C/T) genotypes, their haplotypes and risk of GC {#s0075}
-----------------------------------------------------------------------------------------------------------------------

Frequency of genotypes and alleles were in Hardy--Weinberg equilibrium in controls (ϰ^2^ test: p-value for patients with FD = 0.547, 0.491; HC = 0.945, 0.574 for polymorphisms of -1082 G/A and -819/592 C/T, respectively). Genotyping distribution of IL-10-1082 G/A was comparable in patients with GC than FD and HC ([Table 2](#t0010){ref-type="table"}). In case of IL-10-819/592 C/T polymorphism, homozygous variant (TT) was commoner among patients with GC and conferred twofold risk in reference to homozygous wild (CC) genotype \[36/200 (18%) vs. 30/250 (12%); p = 0.020, OR 1.99, 95% CI 1.11--3.55\] in comparison to HC. On applying dominant model, T allele carriage (CT + TT) was also commoner in patients with GC than HC \[139/200 (69.5%) vs. 149/250 (59.6%); p = 0.030, OR 1.54, 95% CI 1.04--2.29\] in reference to CC ([Table 2](#t0010){ref-type="table"}).

 Haplotypes were evaluated for IL-10-1082 G/A, -819 C/T and -592 C/A (-819 and -592 are in linkage disequilibrium) polymorphisms located in the same gene with emphasis on combination of variants, which might be more likely to influence change in IL-10 level. Four haplotypes, over-producers (GCC and GTA), intermediate (ACC) and under-producer (ATA) were constructed. Frequency of haplotypes was comparable among cases and controls as shown in [Fig. 1](#f0005){ref-type="fig"}.

3.6. Association between pro- (IL-8) and anti-inflammatory (IL-10) gene polymorphisms and risk of GC in relation to *H. pylori* infection {#s0080}
-----------------------------------------------------------------------------------------------------------------------------------------

Among *H. pylori-*infected subjects, frequency of IL-8-251 AA genotypes was commoner among patients with GC than HC (28/105 \[26.7%\] vs. 22/168 \[13.1%\], p = 0.011, OR = 2.47 \[95% CI = 1.23--4.96\]). The remaining genotypes had comparable frequency among different groups ([Table 3](#t0015){ref-type="table"}).

Frequency of IL-10-1082 G/A genotypes was similar among groups with and without *H. pylori* infection ([Table 3](#t0015){ref-type="table"}). In the case of IL-10-819/592 C/T genotypes, though the IL-10-819 allele T carriage was associated with higher risk of GC in the presence of *H. pylori* (p = 0.018, 2.3 \[1.16--4.5\]), the IL-10-819 genotypes did not confer any risk in the absence of *H. pylori* ([Table 3](#t0015){ref-type="table"}).

3.7. Relationship between pro- IL-8 (-251 T/A) and anti-inflammatory IL-10 (-1082 G/A and -819 C/T) genotypes and serum IL-8 and IL-10 levels {#s0085}
---------------------------------------------------------------------------------------------------------------------------------------------

Subjects with heterozygous (TA) and A allele carriage had higher levels of serum IL-8 than those with TT genotypes (median \[min.--max.\]; TA vs. TT; 56.1 \[4.24--319.46\] vs. 32.23 \[4.67--311.03\], p \< 0.001 and A allele carriage vs. non-carriage; 54.55 \[4.24--319.46\] vs. 32.23 \[4.67--311.03\], p \< 0.001, respectively). However, homozygous variant (AA) was comparable to TT variant (AA; 45.61 \[6.44--234.46\], p = 0.148, [Fig. 2](#f0010){ref-type="fig"}A).

Subjects having the IL-10-1082 G/A with homozygous variant (AA) and A allele carriage had lower IL-10 levels than those with the homozygous wild (GG) genotype (8.99 \[0.19--94.02\] and 10.29 \[0.15--98.45\] vs. 14.9 \[1.1--88.36\], p = 0.023 and 0.037, [Fig. 2](#f0010){ref-type="fig"}B; respectively). However, IL-10 levels were comparable among IL-10-819 C/T genotypes ([Fig. 2](#f0010){ref-type="fig"}C). Variations in serum IL-10 levels were also observed at the IL-10 (-1082 G/A, -819/-592 C/T \[C/A\]) haplotypes level ([Fig. 2](#f0010){ref-type="fig"}D), i.e., subjects having ATA + haplotypes had lower IL-10 levels than did GCC + (7.75 \[0.15--94.32\] vs. 13.23 \[1.1--97.54\], p = 0.038).

3.8. Serum levels of IL-8, IL-10 and IL-8/IL-10 ratio among cases and controls in relation to *H. pylori* infection {#s0090}
-------------------------------------------------------------------------------------------------------------------

Serum levels of IL-8, IL-10 and IL-8/IL-10 ratio were different among cases and controls (p \< 0.001). Patients with GC had higher level of cytokines than HC (58.31 \[6.44--319.45\] vs. 26.33 \[4.67--277.62\], p = 0.001 for IL-8 and 16.83 \[1.1--98.45\] vs. 4.22 \[0.15--61.4\], p \< 0.001 for IL-10) but comparable to FD (55.09 \[4.24--318.96\] and 20.49 \[2.46--98.09\] pg/ml, p = ns), respectively. However, IL-8/IL-10 ratio was lower among patients with GC than HC but higher than FD (3.7 \[0.18--38.41\] vs. 6.59 \[0.98--130.2\], p \< 0.001 and 4.22 \[0.15--61.4\], p \< 0.01; respectively, [Fig. 3](#f0015){ref-type="fig"}).

Serum IL-10 and IL-8/IL-10 ratio were higher among *H. pylori*-infected and non-infected GC than HC, though serum IL-8 was only higher among *H. pylori* non-infected GC ([Fig. 4](#f0020){ref-type="fig"}A and B). Serums IL-8 and IL-10 were comparable among *H. pylori*-infected and non-infected GC than FD.

3.9. Association between gene polymorphisms, serum levels and histological findings {#s0095}
-----------------------------------------------------------------------------------

Carriage of IL-8 A, IL-10 A and -819 T alleles had no relationship with the presence of GC (intestinal or diffuse) and gastritis among patients with GC. IL-8-251 A allele carriage was more frequent among patients with GC having IM than those without (49 \[76.6%\] vs. 68 \[59.6%\], p = 0.007, OR = 2.24 \[2.0--4.91\]) though the other genotypes were comparable. Serum levels of pro- and anti-inflammatory cytokines and their ratio were also comparable among patients with GC with or without IM and gastritis.

4. Discussion {#s0100}
=============

The present study shows that (1) homozygous variant (AA) of pro-inflammatory (IL-8)-251 T/A gene polymorphism was commoner among patients with GC than HC, particularly in the presence of *H. pylori* and IM than those without, (2) patients with GC more often had homozygous variant (TT) and T allele carriage of anti-inflammatory (IL-10) -819/592 C/T polymorphism even in the presence of *H. pylori* infection, (3) circulatory IL-8 and IL-10 were higher; however, serum IL-8/IL-10 ratio was lower among patients with GC than HC but higher than FD, (4) subjects with IL-8-251 T/A, heterozygous (TA) and A allele carriage had higher levels of IL-8 whereas subjects having the IL-10-1082 G/A, homozygous (AA), A allele carriage \[GA + AA\]) and ATA^+^ haplotypes had lower levels of IL-10.

Genetic factors may play an important role in pathogenesis of GC ([@bb0070]). The presence of pro-inflammatory cytokine (IL)-8-251 AA genotype increased transcriptional activity of the IL-8 promoter site along with *H. pylori* infection in in-vitro assay ([@bb0050]). Several recent studies showed an association between IL-8 gene promoter -251 T/A polymorphism and GC ([@bb0210]). However, the results are contradictory. We found that homozygous IL-8 AA variant was commoner among patients with GC, a finding similar to two recent meta-analysis by [@bb0210] and [@bb0140]. In another meta-analysis, Asian studies also showed higher risk of GC but the pooled effect of studies on Europeans showed conflicting results ([@bb0210]). IL-8-251 AA genotypes were also higher among patients with GC having *H. pylori* infection and IM in our study, similar to the finding of a meta-analysis ([@bb0135]). Furthermore, this genotype was comparable among patients with GC and controls in relation to gastritis, Lauren\'s type of tumor and in the absence of *H. pylori*. However, two meta-analyses showed results discordant with our observations ([@bb0210; @bb0230]). Possible reasons for such discordant findings might be related to ethnic variations. There were differences in genetic make-up among Asians including Indians, and other races ([@bb0080]). These observations suggest that Asians (China, Japan, Korea) including Indians have similar relationship between IL-8-251 T/A genotypes and GC, though the incidence of GC is lower among Indians than other Asian countries.

It is suggested that the ability of individuals to produce high levels of IL-8 is partly determined by the IL-8-251 A allele carriage (act as an over-producer), which might increase the risk of GC. We observed that patients with GC had higher levels of IL-8 than HC though comparable to FD as shown by [@bb0185]. In our study, subjects with heterozygous IL-8-251TA, A allele carriage, *H. pylori* infection and IM had higher levels of IL-8 than those without. These observations were also supported by some other studies ([@bb0235; @bb0200]). These findings may suggest that IL-8 cytokine may help in promoting the development of *H. pylori*-associated gastritis, IM and GC as suggested by [@bb0040]. These observations also suggest that GC and FD show similar progression of IL-8 related inflammation. Our findings suggest that IL-8-251 AA genotype and its serum levels may be an important pro-inflammatory biomarker of GC susceptibility among Indians.

Anti-inflammatory IL-10 cytokine is an immune-regulatory and immune-suppressive cytokine ([@bb0155]). It has been reported that IL-10 SNPs -1082 A/G, -819(-592) C/T(C/A) may influence immune function and alter the disease progression ([@bb0115; @bb0175]). In our study, frequency of IL-10-1082 G/A genotype was similar among patients with GC and controls. Homozygous TT and T allele carriage of IL-10-819 C/T polymorphism was frequent among patients with GC than HC. Our result was similar to Caucasian studies; it was, however, contradictory to other Asian data ([@bb0160; @bb0075; @bb0220; @bb0225]). We have also found that four haplotypes (GCC, ACC, GTA and ATA) of these polymorphisms of IL-10 were comparable in all groups.

Cytokine (IL-10) gene polymorphisms with *H. pylori* infection also influence the development of pre-cancerous lesions like chronic gastritis, IM and finally progression of GC ([@bb0175]). In our study, IL-10-819 T allele carriage was commoner among *H. pylori* sero-positive patients but similar in sero-negative patients with GC. A recent meta-analysis reported that IL-10-819 TT variant was not associated with GC in the absence of *H. pylori* but protective against GC susceptibility among individuals infected with *H. pylori* ([@bb0225]). These observations might suggest that *H. pylori* infection is not a sole factor for development of GC. Some other factors, especially host genetic background, may also play a significant role. We have also observed that there was no association between IL-10 gene polymorphisms and IM, gastritis and Lauren\'s tumor type among patients with GC, similar to a Chinese study and a meta-analysis ([@bb0225; @bb0130]). However, a few studies did contradict our observation ([@bb0160; @bb0110]). Racial and genetic difference and type II statistical error might explain this discordance. However, IL-10-1082 A allele carriage was commoner among patients with gastritis (patients with GC and FD both) than those without in our analysis. This observation is supported by one study from our center among patients with pre-cancerous lesions (gastritis) of prostate cancer ([@bb0115]). Briefly, high frequency of IL-10-1082 A and -819 T alleles (lower secretor of IL-10) promote inflammation and risk of cancer development.

We also found that patients with GC had higher IL-10 level than HC though comparable to patients with FD. Two previous studies (one from Japan and the other from Italy) with similar findings suggested that elevated levels of IL-10 was associated with a worse prognosis of GC, independent of their tumor stage ([@bb0060; @bb0205]). Subjects having IL-10-1082 AA homozygous, A allele carriage and haplotype ATA^+^ had lower IL-10 levels in our study; these findings are in accordance with the study by [@bb0175]. In our data, serum IL-10 was also higher in *H. pylori* sero-positive subjects. These suggest that *H. pylori-*induced host immune response may influence the development of pre-cancerous lesions and its progression, where IL-10 cytokine may play an important role.

Imbalance between pro- and anti-inflammatory cytokines plays an important role in the development of chronic atrophic gastritis, IM and their progression to GC ([@bb0120]). This may be the first study to determine the IL-8/IL-10 ratio as a biomarker of gastric carcinogenesis. In our study, patients with GC had lower IL-8/IL-10 ratio than HC but had higher ratio than FD. Furthermore, IL-8/IL-10 ratio was also lower among patients with GC in relation to *H. pylori* infection than those without. These observations suggest that IL-8/IL-10 ratio can be used as a biomarker of gastric carcinogenesis.

In summary, our findings suggest that IL-8 and IL-10 gene polymorphisms and their serum levels may lead to an imbalance between the pro-inflammatory and anti-inflammatory cytokine responses which might influence the susceptibility to GC. Ethnic differences in the frequency of host cytokine gene polymorphisms may explain variation in frequency of GC in spite of high frequency of *H. pylori* infection in different parts of the world. More multi-ethnic studies addressing this issue are needed.

We thank all the patients and volunteers who participated in our study. SK thanks the Indian Council of Medical Research for providing fellowship (No. 3/2/2/209/2013/NCD-III).
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###### 

Demographical and histological characteristics in patients and controls.

                                                                                   GC (n = 200)      FD (n = 182)      HC (n = 250)      p-Value
  -------------------------------------------------------------------------------- ----------------- ----------------- ----------------- ------------------------
  Age in years (mean ± S.D.)                                                       53.3 ± 10.38      49.19 ± 9.67      51.54 ± 10.38     GC vs. FD \< **0.001**
  GC vs. HC = 0.090                                                                                                                      
  Gender                                                                                                                                 
   Male                                                                            142 (71.0%)       118 (64.8%)       176 (70.4%)       GC vs. FD = 0.789
   Female                                                                          58 (29.0%)        64 (35.2%)        74 (29.6%)        GC vs. HC = 0.197
  BW in kg (mean ± S.D.)                                                           46.05 ± 15.17     62.17 ± 21.25     65.12 ± 15.36     **\< 0.001**
  Intestinal metaplasia[a](#tf0005){ref-type="table-fn"}                           64/178 (36.0%)    16/179 (8.9%)     --                \< 0.001
  Presence of gastritis[a](#tf0005){ref-type="table-fn"}                           115/176 (65.3%)   131/175 (74.9%)   --                0.062
  Severity of gastritis                                                                                                                  
   Mild                                                                            85 (73.9%)        108 (82.4%)       --                0.984
   Moderate                                                                        24 (20.9%)        20 (15.3%)                          0.797
   Severe                                                                          6 (5.2%)          3 (2.3%)                            0.749
  Lauren classification of GC[a](#tf0005){ref-type="table-fn"}                                                                           
   Diffuse                                                                         75 (42.6%)        --                --                
   Intestinal                                                                      92 (52.3%)                                            
   Unclassified                                                                    9 (5.1%)                                              
  ***H. pylori* IgG seropositivity**                                                                                                     
   IgG ELISA                                                                       105/176 (59.7%)   121/182 (66.5%)   168/250 (67.2%)   0.235
   Anti-*H. pylori* IgG levels in EIU among sero-positive subjects (mean ± S.D.)   55.11 ± 38.5      56.3 ± 35.12      42.17 ± 30.05     GC vs. FD = 0.752
  GC vs. HC \< **0.001**                                                                                                                 

Abbreviations used: GC, gastric cancer; FD, functional dyspepsia; HC, healthy control; BW, body weight; kg, kilogram; S.D., standard deviation; IgG ELISA, anti-*H. pylori* IgG enzyme linked immunosorbent assay; EIU, enzyme immuno unit.

Bold data indicates significant at P-value \< 0.05.

Histology data were not available in some patients.

###### 

Genotype frequency of pro- (IL-8-251 T/A) and anti- (IL-10-1082 G/A & -819/592 C/T) inflammatory polymorphism and risk of gastric cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
                                       GC\           FD\           HC\           GC vs. FD OR (95% CI)   GC vs. HC OR (95% CI)
                                       (n = 200)     (n = 182)     (n = 250)                             
  ------------------------------------ ------------- ------------- ------------- ----------------------- ----------------------------------------------------
  *IL-8-251 T/A*                                                                                         

  TT (under-producer)^⁎^               67 (33.5%)    58 (31.9%)    93 (37.2%)    1(Reference)            1(Reference)

  TA (intermediate)                    86 (43%)      88 (48.4%)    122 (48.8%)   0.85 (0.53--1.34)       0.98 (0.64--1.49)

  AA (over-producer)                   47 (23.5%)    36 (19.8%)    35 (14%)      1.13 (0.65--1.98)       1.86 (1.09--3.19)[a](#tf0010){ref-type="table-fn"}

  A allele carriers vs. non-carriers   133 (66.5%)   124 (68.1%)   157 (62.8%)   0.93 (0.61--1.42)       1.1 4 (0.78--1.68)

                                                                                                         

  *IL-10--1082 G/A*                                                                                      

  GG (over-producer)^⁎⁎^               30 (15%)      25 (13.7%)    43 (17.2%)    1(Reference)            1(Reference)

  GA (intermediate)                    96 (48%)      90 (49.5%)    122 (48.8%)   0.89 (0.48--1.72)       1.13 (0.66--1.93)

  AA (under-producer)                  74 (37%)      67 (36.8%)    85 (34%)      0.92 (0.49--1.72)       1.25 (0.71--2.19)

  A allele carriers vs. non-carriers   170 (85%)     157 (86.3%)   207 (82.8%)   0.90 (0.51--1.6)        1.18 (0.71--1.9)

                                                                                                         

  *IL-10--819/592 C/T*                                                                                   

  Homozygous wild (CC)^⁎⁎⁎^            61 (30.5%)    51 (28%)      101 (40.4%)   1(Reference)            1(Reference)

  Heterozygous (CT)                    103 (51.5%)   95 (52.2%)    119 (47.6%)   0.91 (0.57--1.44)       1.43 (0.95--2.17)

  Homozygous variant (TT)              36 (18%)      36 (19.8%)    30 (12%)      0.84 (0.46--1.51)       1.99 (1.11--3.55)[b](#tf0015){ref-type="table-fn"}

  T allele carriers vs. non-carriers   139 (69.5%)   131 (72%)     149 (59.6%)   0.88 (0.57--1.38)       1.55 (1.04--2.29)[c](#tf0020){ref-type="table-fn"}
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations used: GC, gastric cancer; FD, functional dyspepsia; HC, healthy control; OR, age and gender matched odds ratio; 95% CI = 95% confidence interval; \*TT, \*\*GG and \*\*\*CC taken as a reference for IL-8, IL-10--1082 and − 819/592 respectively: for risk analysis assuming no associations with disease outcome (OR = 1).

p-Value = 0.023.

p-Value = 0.020.

p-Value = 0.030.

###### 

Genotype frequency of IL-8 and IL-10 in relation to *H. pylori* seropositivity.

                         GC (n = 176)                          FD (n = 182)   HC (n = 250)                                                                                             
  ---------------------- ------------------------------------- -------------- ----------------------- ----------------------- -------------------------------------------------------- -----------------------
  *IL-8-251 T/A*                                                                                                                                                                       
  TT\*                   33                                    26             37, 1 (ref)             21, 1 (ref)             64, 1 (ref)                                              29, 1 (ref)
  TA                     44                                    30             59, 1.26 (0.61--2.57)   29, 1.1 (0.42--2.89)    82, 1.04 (0.59--1.82)                                    40, 0.84 (0.41--1.29)
  AA                     28[a](#tf0025){ref-type="table-fn"}   15             25, 0.84 (0.45--1.54)   11, 0.84 (0.39--1.8)    22, 2.47 (1.2--4.96)[a](#tf0025){ref-type="table-fn"}    13, 1.29 (0.52--3.2)
  A allele carriers      72                                    45             84, 0.96 (0.55--1.69)   40, 1.7 (0.48--2.76)    104, 1.34 (0.8--2.25)                                    53, 1.78 (0.69--1.64)
                                                                                                                                                                                       
  *IL-10-1082 G/A*                                                                                                                                                                     
  GG\*\*                 17                                    6              16, 1 (ref)             9, 1 (ref)              31, 1 (ref)                                              12, 1 (ref)
  GA                     54                                    29             59, 0.86 (0.39--1.9)    31, 1.4 (0.44--4.43)    78, 1.05 (0.51--2.17)                                    44, 2.77 (0.92--8.34)
  AA                     34                                    36             46, 0.69 (0.31--1.57)   21, 2.57 (0.8--8.21)    59, 1.26 (0.64--2.51)                                    26, 1.32 (0.45--3.91)
  A allele carriers      88                                    65             105, 0.79 (0.38--1.6)   52, 1.87 (0.63--5.61)   137, 1.17 (0.61--2.24)                                   70,1.86 (0.66--5.24)
                                                                                                                                                                                       
  *IL-10--819/592 C/T*                                                                                                                                                                 
  CC\*\*\*               33                                    18             36, 1 (ref)             15, 1 (ref)             65, 1 (ref)                                              36, 1 (ref)
  CT                     61                                    32             65, 0.86 (0.47--1.6)    30, 1.17 (0.51--2.68)   94, 1.97 (0.94--4.11)                                    28, 2.44 (0.86--6.9)
  TT                     11                                    21             16, 1.14 (0.53--2.5)    20, 0.57 (0.2--1.6)     9, 1.49 (0.98--4.65)                                     18, 0.26 (0.73--2.2)
  T allele carriers      72[b](#tf0030){ref-type="table-fn"}   53             46, 0.92 (0.52--1.6)    85, 0.96 (0.43--2.12)   103, 2.3 (1.16--4.59)[b](#tf0030){ref-type="table-fn"}   46, 1.44 (0.86--2.4)

Abbreviations used: + ve, seropositive; − ve, seronegative; N, number of genotype; OR, odds ratio; 95% CI = 95% confidence interval; ref., reference; GC, gastric cancer; FD, functional dyspepsia; HC, healthy control; \*TT, \*\*GG and \*\*\*CC taken as a reference for IL-8, IL-10--1082 and − 819/592 respectively: for risk analysis assuming no associations with disease outcome (OR = 1).

p-Value = 0.011; IL-8 (-251 T/A): *GC* vs*. HC*.

p-Value = 0.018; IL-10 (− 819 C/T): *GC* vs*. HC*.
